Comparison between ciprofloxacin and trimethoprim-sulfamethoxazole in antibiotic prophylaxis for transrectal prostate biopsy.
OBJECTIVE
The aim of this study was to compare the efficacies of oral ciprofloxacin administration and oral trimethoprim-sulfamethoxazole (TMP-SMX) regimens in preventing infectious complications following transrectal ultrasound guided biopsy of the prostate.


METHODS
Between 2011-2013, the medical records of 391 (mean age 64.62±7.64 years; range 40 to 87 years) patients who underwent transrectal prostate biopsies, due to suspicion of prostate cancer were retrospectively reviewed. While 500 mg ciprofloxacin was given orally twice daily starting one day before the procedure, continued for 3 days in the first 174 patients (group 1); was given orally twice daily starting one day before the procedure, continued for 3 days in the remaining 217 patients (group 2) for prophylaxis. Urine samples were obtained for urine culture before the procedure. The two groups were compared with respect to findings of urine cultures performed before and after the procedure and complications.


RESULTS
In the ciprofloxacin and groups, any positive urine culture before the procedure was not observed. Complications occured in 93 patients (37 in group 1 and 56 in group 2), after the procedure. Twenty-two (5.6%) (11 in group 1 and 11 in group 2). patients were admitted to our clinic because of high fever occurring after biopsy. Nine ciprofloxacin-treated (5.2%) and 16 TMP-SMX-treated (7.4%) patients had severe dysuria after the procedure. Twenty-one ciprofloxacin recipients (12.1%) and 40 TMP-SMX recipients (18.4%) had macroscopic hematuria. In the ciprofloxacin and TMP-SMX groups, the incidences of new culture positivity were 4% (n=7) and 2.8% (n=6) after the procedure, respectively. All of the isolated bacteria was Escherichia coli. While 11 patients were hospitalized due to signs of complicated urinary tract infections, and 2 patients were treated as outpatients. Rectal bleeding that did not require any intervention was observed in a patient 8 hours after biopsy. SIRS findings were detected in two patients. There were no significant differences between the two groups with respect to age, prostate volume, prostate spesific antigen (PSA) levels, and results of urine culture performed after the procedure (p>0.05).


CONCLUSIONS
Despite the increasing resistance to antibiotics, ciprofloxacin and TMP-SMX are effective prophylactic treatment modalities for transrectal prostate biopsy. Both three-day ciprofloxacin and TMP-SMX regimens seem to be equally effective in the antibiotic prophylaxis for transrectal prostate biopsy.
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Doğan
D
Atılgan
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Yusuf
Y
Gençten
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Engin
E
Kölükçü
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Şahin
Ş
Kılıç
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Nihat
N
Uluocak
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Bekir Süha
BS
Parlaktaş
Department of Urology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
Fikret
F
Erdemir
Ciprofloxacin; prophylaxis; prostate biopsy; trimethoprim-sulfamethoxazole; urinary tract infection